Envitas AAIT - a Powerful Immunotherapy for CancerAAIT is an acronym for autologous adoptive immune therapy and describes a therapyconceived from a patient’s blood, which is eventually re-infused during treatment. Thereare a plethora of strategies for immunotherapy and just as many treatments that belongunder the heading “autologous adoptive immunotherapy.” That said – not all optionsmeasure up to our standard..Envita’s immunotherapy, AAIT, involves 4 major cell types including: • Natural killer cells • Natural killer T cells • Cytokine-induced killer cells • Cytotoxic T lymphocytesThe inclusion of Natural killer cells (NKs) and Natural killer T cells (NKTs) are thestrategic focus of Envita’s AAIT immunotherapy serums.Natural Killer Cells Important in Cancer Prognosis of CancerWhen NK cell numbers and functionality are low, cancer patients are predisposed tomore aggressive tumor growth. And, as disease progresses, such declines are likely tocontinue. In both animal and human clinical trials, we have seen that by restoring NKand NKT function leads to enhanced cellular immune tumor-response and higherpatient survival rates.Keys to Envitas AAIT Uniqueness1) Envitas protocol for AAIT is regulated to optimize the expansion of natural killer cells- the most potent cancer fighting component of the cellular immune system. Most
immune therapies do necessarily use natural killer cells, however, those that do onlyexpand them in sparse numbers with little activation.2) Envitas AAIT protocol demands only 4-5 weeks to grow these cells, so patients canexpect to experience benefits quickly. Moreover, while other immune therapiesadminister approximately 100-200 million cells per treatment, Envita delivers roughly100 times as many during the course of treatment.3) Myriads of published research studies demonstrate the effects of adoptive immunetherapy in cancer patients by which Envita has identified and improved upon the mosteffective applications. Company protocol eschews the highest-level of procedure for theexpansion and application of cells for each immunotherapy treatment.4) In contrast to other published immune therapies, Envitas AAIT is the only one thatcan be administered as a “stand-alone.” Moreover, it may also be administered inconjunction with other therapies to enhance the cells’ effects in patients – a huge andincomparable benefit. Envitas AAIT therapy is not focused solely on expanding cells inthe lab; rather, our intention is to keep them active until reintroduced into the patient’sbody.5) Envita’s AAIT guarantees far greater tumor kill, or cytotoxicity than that of othertouted cancer cell vaccines / immunotherapy treatments found worldwide. Briefly, thismeans Envita’s activated natural killer cells in AAIT deliver shockingly higher tumorobliteration. 6) In conclusion, the most direct means with which to compare Envita’s proprietary immunotherapy against the others includes its: a. Quality - based on cytoxicity (how much tumor the immune system can kill). Envita’s AAIT immunotherapy consistently delivers “significantly greater tumor eradication. b. Quantity (how many cells you get back) – Envita’s AAIT immunotherapy delivers 100 times the cell dosage than all others. c. Sterility (quality control measures) – Envita AAIT immunotherapy is guaranteed to be contaminant free.If you have any inquiries with particular regard to Envitas AAIT immunotherapy, pleaseconsult Envita’s team of physicians and patient educators. This immunotherapy isutilized at Envita’s international cancer center in Mexico.